Publication:
Neurally adjusted ventilatory assist in patients with acute respiratory failure: study protocol for a randomized controlled trial

Thumbnail Image

Date

2016

Journal Title

Journal ISSN

Volume Title

Publisher

BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Villar, J., J. Belda, J. Blanco, F. Suarez-Sipmann, J. M. Añón, L. Pérez-Méndez, C. Ferrando, et al. 2016. “Neurally adjusted ventilatory assist in patients with acute respiratory failure: study protocol for a randomized controlled trial.” Trials 17 (1): 500. doi:10.1186/s13063-016-1625-5. http://dx.doi.org/10.1186/s13063-016-1625-5.

Research Data

Abstract

Background: Patient-ventilator asynchrony is a common problem in mechanically ventilated patients with acute respiratory failure. It is assumed that asynchronies worsen lung function and prolong the duration of mechanical ventilation (MV). Neurally Adjusted Ventilatory Assist (NAVA) is a novel approach to MV based on neural respiratory center output that is able to trigger, cycle, and regulate the ventilatory cycle. We hypothesized that the use of NAVA compared to conventional lung-protective MV will result in a reduction of the duration of MV. It is further hypothesized that NAVA compared to conventional lung-protective MV will result in a decrease in the length of ICU and hospital stay, and mortality. Methods/design This is a prospective, multicenter, randomized controlled trial in 306 mechanically ventilated patients with acute respiratory failure from several etiologies. Only patients ventilated for less than 5 days, and who are expected to require prolonged MV for an additional 72 h or more and are able to breathe spontaneously, will be considered for enrollment. Eligible patients will be randomly allocated to two ventilatory arms: (1) conventional lung-protective MV (n = 153) and conventional lung-protective MV with NAVA (n = 153). Primary outcome is the number of ventilator-free days, defined as days alive and free from MV at day 28 after endotracheal intubation. Secondary outcomes are total length of MV, and ICU and hospital mortality. Discussion This is the first randomized clinical trial examining, on a multicenter scale, the beneficial effects of NAVA in reducing the dependency on MV of patients with acute respiratory failure. Trial registration ClinicalTrials.gov website (NCT01730794). Registered on 15 November 2012. Electronic supplementary material The online version of this article (doi:10.1186/s13063-016-1625-5) contains supplementary material, which is available to authorized users.

Description

Keywords

Acute respiratory failure, Neurally adjusted ventilatory assist, Ventilator-free days, Lung-protective ventilation, Assist ventilation, Liberation from mechanical ventilation

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories